Faculty Opinions recommendation of Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men.

Osteoporosis is a growing health concern in the United States, with an enormous impact on morbidity and mortality. Despite published guidelines to aid clinicians in its management, several controversies remain. Many trials evaluate surrogate measures of bone strength rather than more clinically relevant outcomes, including fracture. Furthermore, the role of combination and sequential therapy remains unclear. Limited data are available regarding appropriate duration of therapy, management of osteoporosis in men, and treatment of glucocorticoid-induced osteoporosis. The development of unique therapeutic agents could potentially revolutionize the treatment of osteoporosis. Once yearly zoledronic acid may provide advantages over existing therapies. Because of limitations with existing selective estrogen receptor modulators, the search for agents with better efficacy and safety profiles has led to the development of several new medications within this class. Finally, denosumab, a monoclonal antibody to receptor activator for nuclear factor-kappa B ligand, also represents a novel therapeutic option for osteoporosis.

Download Full-text

Elemental Mapping Of Bone Strontium In Rats Treated With Strontium Ranelate And Strontium Citrate Using 2D Micro-XRF And 3D Dual Energy K-edge Subtraction X-ray Imaging

10.32920/ryerson.14656218 ◽

2021 ◽

Author(s):

Daniel Arturo Cardenas

Keyword(s):

Strontium Ranelate ◽

Dual Energy ◽

Therapeutic Effects ◽

Sprague Dawley ◽

Treatment Of Osteoporosis ◽

3D Images ◽

X Ray ◽

X Ray Imaging ◽

Sprague Dawley Rats ◽

Animal Bones

Strontium-based medications, such as strontium ranelate, have been shown to have therapeutic effects in the treatment of osteoporosis, other strontium salts are assumed to have similar effects on bone health. The objective of this study was to compare the distribution of strontium in animal bones following administration of strontium ranelate and strontium citrate. Humerus bones were collected from female Sprague-Dawley rats that were dosed daily over ten weeks with strontium ranelate and strontium citrate, and no strontium (control). Bones were imaged using 2D micro-XRF and 3D dual energy KES X-ray imaging. The 2D imaging revealed differences in strontium and calcium levels between samples from treated and non-treated animals (푝 < 0.001). 3D images obtained showed that strontium was observed to be largely present in the trabecular regions under the epiphyseal plate with concentrations of approximately 5 to 15 mg/cm3 in the bones of both strontium treated groups. The thickness of the strontium layers below the growth plate in both the strontium ranelate and strontium citrate sample were not significantly different (푝 = 0.9201). Both imaging studies performed in this work showed that strontium from both salts is heterogeneously distributed in newly formed bone during treatment.

Download Full-text